Japan OKs apixaban to prevent stroke, embolism with Afib

12/27/2012 | Pharmaceutical Business Review Online

Pfizer and Bristol-Myers Squibb obtained approval from Japanese regulators to market the anticoagulant apixaban for ischemic stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation. The approval was based on positive results of the late-stage ARISTOTLE trial. Apixaban has also been approved in Europe and Canada.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ